Clinical Trials Directory

Trials / Completed

CompletedNCT04777643

Sex Differences in Neural Response to Cannabidiol

Status
Completed
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
19 (actual)
Sponsor
Yale University · Academic / Other
Sex
Female
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

This is a randomized, double-blind, within-subjects, cross-over design to assess neural changes following a single dose of cannabidiol (CBD) (600mg) versus placebo among healthy female volunteers.

Conditions

Interventions

TypeNameDescription
DRUGCannabidiolParticipants will receive a single 600mg oral dose of Epidiolex (cannabidiol) 2 hours prior to fMRI scanning.
OTHERPlaceboParticipants will receive a single oral dose of placebo 2 hours prior to fMRI scanning.

Timeline

Start date
2022-06-07
Primary completion
2023-04-27
Completion
2023-04-27
First posted
2021-03-02
Last updated
2023-12-21

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04777643. Inclusion in this directory is not an endorsement.